Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 1, 2012, Pages 213-217

  Gianotti, Nicola ^a   Galli, Laura ^a   Racca, Sara ^a   Salpietro, Stefania ^a   Cossarini, Francesca ^a   Spagnuolo, Vincenzo ^a,b   Barda, Beatrice ^a,b   Canducci, Filippo ^a   Clementi, Massimo ^a,b   Lazzarin, Adriano ^a,b   Castagna, Antonella ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antiretroviral therapy; HIV 1 viral load; Immune recovery; kPCR; Virological failure

Indexed keywords

VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LIMIT OF QUANTITATION; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; VIREMIA; VIRUS LOAD; BLOOD; FEMALE; MIDDLE AGED; RECURRENT DISEASE; RISK FACTOR; TREATMENT FAILURE; VIROLOGY;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK FACTORS; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; VIREMIA;

EID: 84859178656     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr422     Document Type: Article

References (9)

1. EACS Executive Committee. European Guidelines for the Clinical Management and Treatment of HIV-Infected Adults inEurope, Version 5-4, 2011. http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59:eacs-guidelines&catid=37:guidelines&Itemid=41 (8 August 2011, date last accessed).
2. Department of Health and Human Services Panelon Antiretroviral Guidelines for Adult and Adolescents.Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents,January10,2011.http://www.aidsinfo.nih.gov/ContentFiles/Adult and AdolescentGL.pdf(8August2011,datelastaccessed).
3. Thompson MA,Aberg JA,Cahn P et al. Antiretroviral treatment of adult HIVinfection:2010recommendations of the International AIDS Society-USApanel.JAMA 2010;304:321-33.
4. Maldarelli F,Palmer S,King MS et al. ART suppres sesplasma HIV-1RNA to as table set point predicted by prethera pyviremia.PLoS Pathog2007;3:e46.
5. Palmer S, Maldarelli F, Wiegand A et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105: 3879-84.
6. Ruelle J, Jnaoui K, Lefévre I et al. Comparative evaluation of the VERSANT HIV-1 RNA 1.0 kinetic PCR molecular system (kPCR) for the quantification of HIV-1 plasma viral load. J Clin Virol 2009; 44: 297-301.
7. Troppan KT, Stelzl E, Violan D et al. Evaluation of the new VERSANT HIV-1 RNA 1.0 assay (kPCR) for quantitative detection of human immunodeficiency virus type 1 RNA. J Clin Virol 2009; 46: 69-74.
8. Murri R, Ammassari A, Gallicano K et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr 2000; 24: 123-8.
9. Antinori A, Cozzi-Lepri A, Ammassari A et al. Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART.Antivir Ther 2004; 9: 291-6.